Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma-Reference-Cited by-同舟云学术

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma

Published:2015-07-25 Issue:1 Volume:11 Page:59-69
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Kramkimel N.,Thomas-Schoemann A.,Sakji L.,Golmard JL.,Noe G.,Regnier-Rosencher E.,Chapuis N.,Maubec E.,Vidal M.,Avril MF.,Goldwasser F.,Mortier L.,Dupin N.,Blanchet B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-015-0375-8.pdf

Reference28 articles.

1. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–14

2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–16

3. Weeraratna AT (2012) RAF around the edges–the paradox of BRAF inhibitors. N Engl J Med 366:271–3

4. da Rocha DS, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH et al (2013) The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 49:1654–61

5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–19

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

2. The value of pharmaceutical expertise in the detection and management of drug interactions with targeted therapies in melanoma;Annales de Dermatologie et de Vénéréologie;2023-12

3. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

4. Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-08

5. Editorial: Novel biomarkers for anticancer therapy;Frontiers in Pharmacology;2023-01-06